Difference between revisions of "Malignant melanoma"
Jump to navigation
Jump to search
(→Regression of melanoma: +main) |
|||
| Line 127: | Line 127: | ||
*[[AKA]] ''maximum tumour thickness''. | *[[AKA]] ''maximum tumour thickness''. | ||
*Depth measured from stratum granulosum to deepest intradermal tumour cell - predictive of survival.<ref name=Ref_PCPBoD8>{{Ref PCPBoD8|595}}</ref> | *Depth measured from stratum granulosum to deepest intradermal tumour cell - predictive of survival.<ref name=Ref_PCPBoD8>{{Ref PCPBoD8|595}}</ref> | ||
Note: | |||
*This differs from how [[squamous cell carcinoma]] thickness is measured. It is measure from the basement membrane.<ref name=Ref_ABPR275>{{Ref ABPR|275}}</ref> | |||
====Clark level==== | ====Clark level==== | ||
Revision as of 16:47, 29 May 2012
Malignant melanoma, also melanoma, is an aggressive type of skin cancer that can be diagnostically challenging for pathologists.
It fits into the larger category of melanocytic lesions which includes many benign entities, a number of which can be difficult to distinguish from melanoma.
General
- Known as the great mimicker in pathology; it may look like many things.
Pathologic prognostic factors
Pathologic predictors for a poor prognosis:[1]
- Tumour thickness (Brewslow thickness) > 1 mm.
- Mitotic rate >1/mm^2.
- Ulceration.
- Regression - >75% of tumour.
- Tumour infiltrating lymphocytes.
- Microsatellitosis - nest of tumour cells > 0.05 mm size, separated from primary tumour >=0.3 mm and <= 2 cm.
- In transist metastasis.
- Lymphovascular invasion.
- Perineural invasion.
Clinical
- ABCD = asymmetric, borders (irregular), colour (black), diameter (large).
Serologic predictors of a poor prognosis:
- Lactate dehydrogenase (LDH) > 200-225 U/L.
- Alumin < 35 g/L.
Microscopic
Metatstatic/non-skin
Features (non-skin):
- Classic appearance of melanoma:
- Loosely cohesive; mix of small nests of cells, single cells.
- Nests often have clefting with surrounding tissue.
- Mix of spindle cells and epithelioid cells:
- +/-Occasional large binucleated cells.
- Cytoplasm with brown pigment (melanin).
- Prominent (large) red nucleoli (like in serous carcinoma of the ovary).
- Marked nuclear pleomorphism - variation in cell size, shape & staining (like in serous carcinoma of the ovary).
- Nuclear pseudoinclusions (like in papillary thyroid carcinoma).
- Loosely cohesive; mix of small nests of cells, single cells.
Notes:
- Can look almost like anything.
- Like it is said that sarcoidosis is in every internal medicine DDx... melanoma is every pathologic DDx
- May have no nuclear atypia.
- Diagnosis is based on architecture (upward spread in the epidermis, single cells, asymmetry).
DDx
- Carcinoma.
- Serous carcinoma - both serous carcinoma and melanoma have a large nucleolus.
- Sarcoma - as may have spindle cells.
- Clear cell sarcoma.
- Metaplastic carcinoma.
- Epithelioid angiosarcoma.
- Lymphoma.
- Other melanocytic lesions.
Images:
Skin
Features (skin):
- Melanocytic differentiation:
- Pigmentation (melanin).
- Nuclear pseudoinclusion.
- Gray cytoplasm.
- Clear (artefactual) halo around cells.
- Architecture:
- Sheeting - diagnostic.
- Asymmetry - as judged from low power magnification.
- Lack of maturation - see below.
- +/-Nuclear atypia - esp. nucleoli.
- May be seen in a Spitz nevus.
- +/-Upward scatter of melanocytes AKA intraepidermal ascent - "cannonball" appearance.
- No diagnostic significance in the following cases:
- Acral sites - see: Acral nevus.
- Histologic evidence of trauma.
- Thick dense stratum corneum.
- No diagnostic significance in the following cases:
Maturation - with depth:
- Nests get smaller.
- Cells get smaller.
- Mitoses decrease.
- Pigmentation decrease.
DDx:
- Epithelioid cell forms:
- Spitz nevus - especially difficult.
- Key differences: maturation and symmetry.
- Melanocytic nevus.
- Spitz nevus - especially difficult.
- Spindle cell forms:
- Spindle cell squamous carcinoma.
- Atypical fibroxanthoma.
- Leiomyosarcoma.
Images:
Regression of melanoma
Main article: Tumour regression
General
- Complete regression without metastases estimated to be 10-20%.[2]
- Common ~25% of cases.[2]
- Complete regression and partial regression >75% of the lesion are a poor prognostic feature.[3]
Microscopic
Features - all required:
- No melanocytes.
- Melanophages.
- Fibrosis.
- Thinned epidermis.
- Telangiectatic vessels.
- Lymphocytes.
Metastatic versus primary
Primary lesions should have:
- Epidermal involvement.
Metastatic lesions classically have:
- Tumour angiotropism (tumours cells cluster around vessels).
- Intravascular invasion.
- No epidermal component.
Note:
- Histology is not definitive for metastatic melanoma vs. primary melanoma; epidermal involvement may be seen in mets.
- History/clinical is important for differentiation.
Breslow thickness
- AKA maximum tumour thickness.
- Depth measured from stratum granulosum to deepest intradermal tumour cell - predictive of survival.[4]
Note:
- This differs from how squamous cell carcinoma thickness is measured. It is measure from the basement membrane.[5]
Clark level
- AKA anatomic level.
- Not as reproducible as Breslow thickness - not used.
Anatomic level - definition:
- I = epidermis only (AKA melanoma in situ).
- II = extends into papillary dermis but does not fill or expand.
- III = fills and expands papillary dermis.
- IV = extends into reticular dermis.
- V = extends into subdermis.
Subtypes
| Subtype name | Key feature | Microscopic additional | DDx | Image | Notes/other |
| Melanoma in situ | confined to epidermis, nuclear atypia | melanocyte enlargement, nuclear hyperchromasia, +/- melanocytes above suprapapillary plate (above basal layer) = "Pagetoid spread" | melanocytic hyperplasia, pagetoid Spitz nevus | (upmc.edu) | lentigo maligna is melanoma in situ[6] on sun damaged skin |
| Malignant melanoma - superficial spreading type | atypical melanocytes at all levels of epidermis + dermis | atypical dermal melanocytes single, in cluster or sheets | compound melanocytic nevus | Image? | Notes/other? |
| Malignant melanoma - lentiginous type | atypical melanocytes prominent along basal keratinocytes + in dermis | nuclear atypia | DDx? | Image? | Notes/other? |
| Malignant melanoma - nodular type | dermal large nodule/sheet | nuclear atypia; may not be prominent in epidermis | metastatic melanoma | Image? | Notes/other? |
| Malignant melanoma - desmoplastic-neurotropic type AKA desmoplastic melanoma | large atypical spindle cells, btw collagen | predominantly dermal | pleomorphic undifferentiated sarcoma (MFH), scar, dermatofibroma, DFSP, leiomyosarcoma, desmoplastic Spitz nevus, sclerosing blue nevus | (upmc.edu) | IHC: rarely S100-, generally Melan A- & HMB-45-; subdivided into mixed desmoplastic melanoma and pure desmoplastic melanoma |
| Malignant melanoma - nevoid type | prominent nucleoli, deep mitoses - high power diagnosis | mimics nevus at low power; "push" elastic fibers downward (unlike benign nevi) | (benign) nevus | Image? | deep HMB-45+ |
| Malignant melanoma - spitzoid type | nested pattern, nuclear atypia, no maturation (large deep cells) | NC ratio increased (vs. Spitz) | Spitz nevus | Image? | Notes/other? |
Subtypes in short
| Subtype name | Key feature |
| in situ | confined to epidermis, unlike all others |
| superficial spreading | above basal layer |
| lentiginous | along basal keratinocytes |
| nodular | nodular dermal lesion |
| desmoplastic-neurotropic | atypical dermal spindle cells |
| nevoid | nevus-like at low power |
| spitzoid | mimics Spitz nevus (at DE junction) |
Electron microscopy
- Melanosomes.
Image(s):
Stains
- Fontana-Masson stain, stains melanin.[7]
- May be useful to differentiate melanin from other brown stuff (e.g. lipofuscin, hemosiderin).
IHC
Standard panel:
- S100 +ve.
- Negative staining pretty much excludes the diagnosis.
- HMB-45 +ve -- esp. deep.
- Melan A (MART-1) +ve.
Others:
- SOX10 +ve -- useful for diff. from excision scar.[8]
- SOX-10 = pan-schwannian and melanocytic marker.
Notes:
- The standard panel above (S100, HMB-45, MART-1) is also positive in other lesions, e.g. cellular blue nevus.
See also
References
- ↑ URL: http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2011/SkinMelanoma_11protocol.pdf. Accessed on: 29 March 2012.
- ↑ 2.0 2.1 Printz, C. (Jul 2001). "Spontaneous regression of melanoma may offer insight into cancer immunology.". J Natl Cancer Inst 93 (14): 1047-8. PMID 11459861.
- ↑ Crowson, AN.; Magro, CM.; Mihm, MC. (Feb 2006). "Prognosticators of melanoma, the melanoma report, and the sentinel lymph node.". Mod Pathol 19 Suppl 2: S71-87. doi:10.1038/modpathol.3800517. PMID 16446717.
- ↑ Mitchell, Richard; Kumar, Vinay; Fausto, Nelson; Abbas, Abul K.; Aster, Jon (2011). Pocket Companion to Robbins & Cotran Pathologic Basis of Disease (8th ed.). Elsevier Saunders. pp. 595. ISBN 978-1416054542.
- ↑ Template:Ref ABPR
- ↑ McKenna, JK.; Florell, SR.; Goldman, GD.; Bowen, GM. (Apr 2006). "Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment.". Dermatol Surg 32 (4): 493-504. doi:10.1111/j.1524-4725.2006.32102.x. PMID 16681656.
- ↑ URL: http://education.vetmed.vt.edu/curriculum/VM8054/labs/Lab2/Examples/exfontana.htm. Accessed on: 5 May 2010.
- ↑ Ramos-Herberth FI, Karamchandani J, Kim J, Dadras SS (September 2010). "SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar". J. Cutan. Pathol. 37 (9): 944–52. doi:10.1111/j.1600-0560.2010.01568.x. PMID 20653825.